Since these human data demonstrated that either the leukotrienes pathway or GPBAR1 were upregulated in patients with NAFLD, we have decided to explore whether their modulation is beneficial in a model of NAFLD/NASH. This evidence concerns the gene GPBAR1 and metabolic dysfunction-associated steatohepatitis.